11 Jun 2012
Why Have a Hepatitis C Test? Cont…
Although the incidence of Hepatitis C in the UK is relatively low, A study conducted using residual sera collected as part of the HPA Sero-epidemiology programme suggested that around 106,000 individuals became infected with hepatitis C between 1986 and 2001 (HPA 2009 report Hepatitis in the UK).
Primary prevention of hepatitis C infection involves a variety of practical measures, some aimed particularly at risk groups, and other more general measures to ensure that the national blood supply is safe through donor selection and screening. Rates of HCV-related serious liver disease are increasing. Unfortunately, many people living with hepatitis C are unaware of their infection status, resulting in a silent reservoir of infection in society.
An important part of the overall strategy to control hepatitis C is to improve awareness of the infection and encourage testing in risk groups. Once diagnosed, effective treatment can help eliminate a persistent infection, in at least some patients, and so reduce the number of infected individuals. Treatment before the onset of recognisable disease reduces the progression to late complications of infection. Patients who respond to therapy by clearing the virus can avoid the risk of serious liver damage. Among patients who do not respond to therapy, the risk of developing long-term liver damage can be reduced by modifying other risk factors, such as alcohol consumption and avoiding infection with other hepatitis causing viruses.
Having a clear strategy is only the first step in achieving a real impact. Equally important is the delivery of interventions and review of their efficiency.
Progress made to date in the UK varies from country to country, reflecting the different stages of implementation of hepatitis C control programmes and the different approaches taken in the different administrations. A four nations approach will encourage the sharing of good practice and help to identify best practice.
The number of deaths in England due to end-stage liver disease (ESLD) or hepatocellular carcinoma (HCC) with any mention of hepatitis C on the death certificate continues to increase. The number of deaths registered has increased from 81 in 1996 to 230 in 2008. The majority of deaths are in men. The number of deaths in women has remained relatively stable over the last decade.
It is clear from the above facts and report from both the Hepatitis C Trust and the Health Protection Agency, that there is a very considerable health gain from the detection of a Hepatitis C infection. A gain to be enjoyed not only by the individual in whom the infection is detected, where if it had remained undiagnosed, might have lead to cirrhosis, cancer and possibly death, but gains also to society, where infection rates remain on the rise, are recognised by the HPA to be a national health risk, and for which detection of each case can lead to treatment, and the prevention of onward transmission of the disease.